0000899243-18-027478.txt : 20181025
0000899243-18-027478.hdr.sgml : 20181025
20181025182533
ACCESSION NUMBER: 0000899243-18-027478
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181023
FILED AS OF DATE: 20181025
DATE AS OF CHANGE: 20181025
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ioannidou Sofia
CENTRAL INDEX KEY: 0001752486
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38707
FILM NUMBER: 181139922
MAIL ADDRESS:
STREET 1: 610 MAIN STREET
STREET 2: 3RD FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664106
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 471514975
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 700 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 61(0)428-338-594
MAIL ADDRESS:
STREET 1: 700 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-10-23
0
0001664106
LogicBio Therapeutics, Inc.
LOGC
0001752486
Ioannidou Sofia
C/O LOGICBIO THERAPEUTICS, INC.
610 MAIN ST., 3RD FLOOR
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2018-10-23
4
C
0
1367413
A
1367413
I
See Footnote
Common Stock
2018-10-23
4
P
0
420000
10.00
A
1787413
I
See Footnote
Series B Convertible Preferred Stock
2018-10-23
4
C
0
2611665
0.00
D
Common Stock
1367413
0
I
See Footnote
Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock.
The Reporting Person is a director of Andera Partners, the company managing BioDiscovery 5. BioDiscovery 5 is the direct beneficial owner of these securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest.
/s/ Matthias Jaffe, as Attorney-in-Fact
2018-10-25